Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease ...

Retrieved on: 2021-04-27 06:56:15

Tags for this article:

Click the tags to see associated articles and topics

Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease .... View article details on hiswai:

Excerpt

Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington's disease pathology; Human ...

Article found on: pipelinereview.com